ArticlePostepy dermatologii i alergologii2025
Comparative efficacy of combined steroid and omalizumab therapy following the surgical treatment of chronic polypous rhinosinusitis in adults.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the mucous membrane of the nose and adjacent cavities. In the treatment of the condition, glucocorticoids are considered a traditional and effective therapeutic drug. Monoclonal antibodies are a promising therapeutic option because they can block specific chemokines. Aim: The aim of the presented study is to assess the comparative efficacy of CRSwNP therapy with combined use of steroids and a biologic agent, omalizumab. Material and methods: One hundred and four participants diagnosed with chronic rhinosinusitis who underwent excision of polyps were involved in two interventional groups of the study. The first group (ST-group) included 56 patients who received 2 injections of Diprospan, while the other group (STO-group) received combined therapy with omalizumab and Diprospan. Sino-Nasal Outcome Test 22 (SNOT-22), assessment of skin functional properties, Modified Lund-Mackay Postoperative Endoscopy Score (MLMES) and computed tomography of nasal sinuses were used to comparatively evaluate the treatment efficacy. Results: The STO-group showed statistically significant improvements across all measured parameters. This suggests that omalizumab may enhance the therapeutic effect of corticosteroids, potentially by stabilizing mast cells and decreasing allergic inflammatory responses more broadly. Conclusions: While more research is necessary to evaluate the cost-effectiveness and long-term safety of this approach, current evidence supports its potential as a more effective treatment modality for severe or refractory cases of CRS. The addition of omalizumab allows for lower cumulative steroid exposure, reducing long-term side effects while maintaining or improving efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.